Amprenavir

Liver Dysfunction in HIV Patients Decreases Drug Metabolism Rate

Published in Hepatitis Weekly, May 22nd, 2000

Amprenavir, a protease inhibitor used for treating patients with the human immunodeficiency virus (HIV), is not completely metabolized by patients with liver diseases such as cirrhosis. As a result, Glaxo Wellcome researchers recommend that HIV patients with liver disorders who take amprenavir should have their dosages adjusted.

"Amprenavir (141W94) is extensively metabolized by P450 cytochromes, specifically, CYP3A4. Because hepatic insufficiency reduces P450 mediated metabolism, the concentrations in plasma of drugs metabolized through this pathway are often increased in subjects with liver disease," said L. Veronese and colleagues at Glaxo Wellcome.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2000-05-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry